Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersInfectious Disease Physician in Syracuse, NY
NPI: 1205952280Primary Practice Location
UNIVERSITY HOSPITAL S U N Y HEALTH SCIENCE CENTER
4900 Broad Rd, Syracuse, NY
Primary Employer
Department of Medicine Medical Serv Grp at SUNY Hlth Sci Ctr Syr In
upstatemedicine.com
HQ Phone
Get M.D. Kristopher's Phone Numberphone_androidMobile
Get M.D. Kristopher's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
National Capital Consortium
fellowship • Infectious Disease
2008 - 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 34 | 54 |
| 2 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 31 | 32 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 20 | 32 |
| 4 | 99223Initial hospital inpatient care, typically 70 minutes per day | 17 | 17 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 16 | 16 |
Authors: Ambika Eranki
Journal: J Antimicrob Chemother
Authors: Angelica Kottkamp, Ruanne Barnabas, Meagan Deming, Helen Stankiewicz Karita, Miriam Laufer, Mark Wener, Connie Celum, Anna Wald, Risa Hoffman, Helen Chu, Alfred Luk
Journal: Ann Intern Med
Publication Date: 2020-12-08
Lead Sponsor: State University of New York - Upstate Medical University
Collaborators: U.S. Army Medical Research and Development Command, Janssen Pharmaceutica N.V., Belgium
Intervention / Treatment: BIOLOGICAL: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
Lead Sponsor: University of Washington
Collaborators: Bill and Melinda Gates Foundation
Intervention / Treatment: DRUG: Azithromycin, DRUG: Folic Acid, DRUG: Ascorbic Acid, DRUG: Hydroxychloroquine Sulfate, DRUG: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Lead Sponsor: SAb Biotherapeutics, Inc.
Collaborators: Department of Health and Human Services, JPEO, Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)
Intervention / Treatment: OTHER: Normal saline, BIOLOGICAL: SAB-185
